Search found 531 matches
- Thu Nov 02, 2017 3:07 pm
- Forum: ImetelChat
- Topic: 4 abstracts on imetelstat at ASH2017
- Replies: 5
- Views: 15183
Re: 4 abstracts on imetelstat at ASH2017
Some of my observations regarding the 4 abstracts: - impact of imet on MDS disease has been refined, while positive effect on TI and HI is confirmed; - the IMerge paper has been co-authored by 5 JnJ employees and 10 researchers/doctors from various hospitals, of which 7 from Europe and 3 from US (in...
- Thu Nov 02, 2017 2:50 pm
- Forum: ImetelChat
- Topic: 4 abstracts on imetelstat at ASH2017
- Replies: 5
- Views: 15183
Re: 4 abstracts on imetelstat at ASH2017
And here are the links and conclusions for each abstract: 4256 Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge) Conclusions: In IPSS Low/Int-1 RBC transfusion dependent MDS patients relapsed...
- Thu Nov 02, 2017 11:58 am
- Forum: ImetelChat
- Topic: 4 abstracts on imetelstat at ASH2017
- Replies: 5
- Views: 15183
4 abstracts on imetelstat at ASH2017
Geron Announces Presentations at American Society of Hematology Annual Meeting Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented MENLO PARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts relate...
- Thu Nov 02, 2017 11:54 am
- Forum: ImetelChat
- Topic: FDA fast track
- Replies: 1
- Views: 2552
Re: FDA fast track
Nice! Plus the strat of expanded Part 1 of IMerge. Expanded Part 1 of IMerge is Open for Patient Enrollment MENLO PARK, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designati...
- Wed Oct 25, 2017 10:30 pm
- Forum: ImetelChat
- Topic: Geron Announces Conference Call to Discuss Third Quarter 2017 Financial Results
- Replies: 0
- Views: 2270
Geron Announces Conference Call to Discuss Third Quarter 2017 Financial Results
MENLO PARK, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2017, on Wednesday, November 1, 2017, after the market close. Geron’s management will also host a conference call for analysts and inves...
- Mon Oct 23, 2017 11:43 pm
- Forum: ImetelChat
- Topic: Geron patent published: Method for identification of sensitivity of a patient to telomerase inhibition therapy
- Replies: 2
- Views: 2404
Re: Geron patent published: Method for identification of sensitivity of a patient to telomerase inhibition therapy
Indeed, Cheng. It is for testing purposes.
- Sun Oct 22, 2017 11:43 pm
- Forum: ImetelChat
- Topic: Geron patent published: Method for identification of sensitivity of a patient to telomerase inhibition therapy
- Replies: 2
- Views: 2404
Geron patent published: Method for identification of sensitivity of a patient to telomerase inhibition therapy
Method for identification of sensitivity of a patient to telomerase inhibition therapy REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Ser. No. 13/124,376, filed Apr. 14, 2011, which is a 371 of PCT Application Serial No. PCT/US09/60526, filed Oct. 13, 2009, which claim...
- Sun Oct 22, 2017 11:21 pm
- Forum: ImetelChat
- Topic: I left this on SA board
- Replies: 2
- Views: 2678
Re: I left this on SA board
Nice post, BP. I share your vision. The things you mention are simple and solid, derived from what we actually know from various publications and telco's. Btw: ESA's only boost red cell production for a while. Or never, because still a large portion of MF and MDS patients don't respond to ESA's (suc...
- Wed Sep 27, 2017 2:02 pm
- Forum: ImetelChat
- Topic: Today's Presentation ~ regarding OS
- Replies: 2
- Views: 3596
Re: Today's Presentation ~ regarding OS
Actually I think it will be more than one step....
- Wed Aug 23, 2017 10:53 am
- Forum: ImetelChat
- Topic: Take aways from today's telco (1 Aug 2017)
- Replies: 8
- Views: 7657
Re: Take aways from today's telco (1 Aug 2017)
You're welcome, Ryan!
Indeed, the latest telco seems to tell us that JnJ is closing in on its target and is carefully choosing its gateway to the market. These early biotech tunnels can be long and dangerous, and proper lighting is not always available....
Indeed, the latest telco seems to tell us that JnJ is closing in on its target and is carefully choosing its gateway to the market. These early biotech tunnels can be long and dangerous, and proper lighting is not always available....
- Fri Aug 04, 2017 6:26 am
- Forum: ImetelChat
- Topic: Take aways from today's telco (1 Aug 2017)
- Replies: 8
- Views: 7657
Re: Take aways from today's telco (1 Aug 2017)
Done. It is in the News and the Commercial section.
- Thu Aug 03, 2017 12:29 pm
- Forum: ImetelChat
- Topic: Take aways from today's telco (1 Aug 2017)
- Replies: 8
- Views: 7657
Re: Take aways from today's telco (1 Aug 2017)
another great comment from Hoosier (SA): 1) Contractually, Janssen could've postponed the primary analysis as long as they desired. Thus, by agreeing to the 3Q18 cut-off date, Janssen is showing some consideration / compassion for Geron's position. 2) I suspect Janssen's recent discussions with FDA ...
- Wed Aug 02, 2017 12:10 pm
- Forum: ImetelChat
- Topic: Take aways from today's telco (1 Aug 2017)
- Replies: 8
- Views: 7657
Re: Take aways from today's telco (1 Aug 2017)
Repost from sdrawkcabeman (YHMB, yesterday) Drug development is an exercise in strategic planning. Tracing the root of the Imet program, we see the strategy being continually refined and the drug proven to be active repeatedly across multiple conditions, and this quite stunning and clear signal in t...
- Tue Aug 01, 2017 7:40 pm
- Forum: ImetelChat
- Topic: Take aways from today's telco (1 Aug 2017)
- Replies: 8
- Views: 7657
Take aways from today's telco (1 Aug 2017)
1 Aug 2017 IMerge Substantial results are observed in the 13 patients subgroup (non-del5q and naïve to HMA): 53.7% achieved 8+ weeks of TI. The non-del8q subgroup represents approximately 85% of all the MDS patients. It seems the imetelstat will beat Best Available Therapy in this group. 20 new pati...
- Tue Aug 01, 2017 5:59 pm
- Forum: ImetelChat
- Topic: PR July 31, 2017: Geron Announces Updates to Imetelstat Clinical Development
- Replies: 2
- Views: 3653
Re: PR July 31, 2017: Geron Announces Updates to Imetelstat Clinical Development
Second comment from Hoosier on SA today: 1) Our 'good problem to have' within IMbark continues as patients remain alive to the extent they can't assess median overall survival. This has been the source of delay in the IMbark primary analysis and subsequent Continuation Decision. Again, it's a good p...
- Tue Aug 01, 2017 5:56 pm
- Forum: ImetelChat
- Topic: PR July 31, 2017: Geron Announces Updates to Imetelstat Clinical Development
- Replies: 2
- Views: 3653
Re: PR July 31, 2017: Geron Announces Updates to Imetelstat Clinical Development
Response from Hoosier on SA on the press release: 1) Lenalidomide's MDS approval is limited to patients with a deletion 5q cytogenetic abnormality. Lenalidomide's safety and efficacy were demonstrated in one single-arm, multicenter clinical trial of 148 patients. The primary endpoint was RBC transfu...
- Tue Aug 01, 2017 11:43 am
- Forum: ImetelChat
- Topic: PR July 31, 2017: Geron Announces Updates to Imetelstat Clinical Development
- Replies: 2
- Views: 3653
PR July 31, 2017: Geron Announces Updates to Imetelstat Clinical Development
Geron Announces Updates to Imetelstat Clinical Development Conference Call Scheduled for 8:00 a.m. ET on Tuesday, August 1 MENLO PARK, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced updates to the clinical development plans for IMerge and IMbark, the ongoi...
- Sun Jul 02, 2017 8:22 pm
- Forum: ImetelChat
- Topic: How to join this board
- Replies: 2
- Views: 5513
Re: How to join this board
Just a reminder for those who want to join, but who found out that the normal registration process has been disabled. Just send an email to info@imetelstat.eu and I will make an account for you.
- Sun Jul 02, 2017 8:20 pm
- Forum: ImetelChat
- Topic: New Imetelstat article
- Replies: 2
- Views: 3873
- Sat Jul 01, 2017 9:51 pm
- Forum: ImetelChat
- Topic: New Imetelstat article
- Replies: 2
- Views: 3873
Re: New Imetelstat article
Thanks, Bio. Interesting article. I will upload it asap.